Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/11/22
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021PRNewsWire • 03/10/22
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology InnovationsPRNewsWire • 02/23/22
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers SymposiumPRNewsWire • 02/17/22
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark GergenPRNewsWire • 01/10/22
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid TumorsPRNewsWire • 12/20/21
Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 12/14/21
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/13/21
Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a BetZacks Investment Research • 11/24/21
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021PRNewsWire • 11/09/21
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual MeetingPRNewsWire • 11/09/21
Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should KnowZacks Investment Research • 11/08/21
A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida TherapeuticsMarket Watch • 10/12/21
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene TherapiesPRNewsWire • 10/12/21
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual MeetingPRNewsWire • 10/01/21
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR SummitPRNewsWire • 08/31/21
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple MyelomaPRNewsWire • 08/30/21
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021PRNewsWire • 08/12/21